Cargando…
Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model
After more than 40 years of use, Praziquantel (PZQ) still remains the drug of choice for the treatment of intestinal and urogenital schistosomiasis. Its anti-parasitic activity resides primarily in the (R)-enantiomer. Hitherto neither the molecular target nor the pharmacokinetic-pharmacodynamic rela...
Autores principales: | Abla, Nada, Keiser, Jennifer, Vargas, Mireille, Reimers, Natalie, Haas, Helmut, Spangenberg, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626502/ https://www.ncbi.nlm.nih.gov/pubmed/28934207 http://dx.doi.org/10.1371/journal.pntd.0005942 |
Ejemplares similares
-
Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome
por: Schneeberger, Pierre H. H., et al.
Publicado: (2018) -
In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium
por: Kovač, Jana, et al.
Publicado: (2017) -
Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
por: Minzi, Omary Mashiku, et al.
Publicado: (2021) -
Praziquantel Treatment of Schistosoma mansoni Infected Mice Renders Them Less Susceptible to Reinfection
por: Nono, Justin Komguep, et al.
Publicado: (2021) -
Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel
por: Amer, Eglal I., et al.
Publicado: (2022)